Summary:
This study will evaluate the long-term safety and tolerability of ALKS 8700 for the treatment of Relapsing Remitting Multiple Sclerosis (RRMS)
Qualified Participants Must:
• Be between 18 and 65 years of age (Adult)
•
Have a confirmed diagnosis of RRMS
Qualified Participants May Receive:
Study-related medical care and investigational drug at no cost and may be compensated for time and travel.